

FOSTAMATINIB tablets (Tavlesse® ▼) for the treatment of chronic immune thrombocytopenia (ITP)

The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of FOSTAMATINIB tablets (Tavlesse® ▼) for the treatment of chronic immune thrombocytopenia (ITP).

GREY

Fostamatinib is indicated for the treatment of chronic ITP in adult patients who are refractory to other treatments.¹

- > This recommendation will be reviewed when the [NICE TA](#) is published.

In the meantime, treatment of chronic ITP should continue to follow local pathways and local formulary choices:

- > Pan Mersey APC Formulary: [Drugs used in platelet disorders](#)

References

1. Grifols UK Ltd. Summary of Product Characteristics; [Tavlesse 100 mg film-coated tablets](#), April 2020. Accessed online 10 September 2020.

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.